Compare Entegris Inc (ENTG) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Medpace Holdings Inc — how do they compare? Entegris Inc trades at $165 (market cap $24.78B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: Entegris Inc is the larger of the two by market cap, and Entegris Inc pays a 0.25% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Entegris Inc for 41 Days and Medpace Holdings Inc for 14 Days on average.
| ENTG | MEDP | |
|---|---|---|
Market Cap | $24.78B | $16.82B |
Volume | 2,648,320 | 223,093 |
Sector | Technology | Health |
52-Week High | $184.00 | $630.19 |
52-Week Low | $68.80 | $393.42 |
Typical Hold Time | 41 Days | 14 Days |
Enterprise Value | $27.99B | $16.44B |
Dividend Yield | 0.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Entegris (ENTG) trades at $165.79, down 0.32% on the day, with strong technical momentum as the stock approaches resistance at $166. The company demonstrates solid fundamentals with Q2 2026 EPS of $0.93 beating expectations by 13%, driven by AI-related semiconductor demand. Revenue remains stable at $3.2B with improving net margins of 9.18%. Recent news highlights institutional accumulation and patent defense successes.
Outlook remains positive with 70% analyst buy ratings and $182.43 consensus target suggesting 10% upside. Key catalysts include Q3 earnings on October 29 and Investor Day on November 9. Risks include elevated valuation multiples (P/E 81.1) and semiconductor cycle sensitivity. The stock offers growth exposure to advanced semiconductor materials with institutional confidence.
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
